CompletedNCT00982982
Effects of Delta-9-THC and Iomazenil in Healthy Humans
It focuses on schizophrenia and currently lists study information in the United States.
Schizophrenia, Mental DisordersDrugFrom 18 Years to 55 Years
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- West Haven, United StatesSee all locations and recruitment
Compensation and expense reimbursement have not been verified for this summary.
Study information
Study start dateStarted: February 11, 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 17
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- EARLY Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00982982
- Official title
- Gamma-Amino Butyric Acid (GABA) Deficits and Vulnerability to Cannabinoid-Induced Psychosis
Recruitment & locations
CompletedWest Haven
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Did this study involve medication?
Yes. The study involved medication, including THC and Iomazenil and Placebo (control).
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedNCT06880328
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in people with Schizophrenia
This study is completed in the United States. It focuses on schizophrenia.
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.